Following injectable cabotegravir availability in 2022, prescriptions increased from 1.1% in 2022 to 2.5% in 2023. “New PrEPmedications are heavily marketed, yet, generic PrEP dominated the ...
About The Study: Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, with generic tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) being the most frequently prescribed ...
Results that may be inaccessible to you are currently showing.